Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

NCT07422857 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

Interventions

DRUG: [18F]-APN-1607

Sponsor

JYAMS PET Research & Development Limited